At the heart of this conceptual advance lies the observation that MPO operates in two distinct structural states—monomeric and dimeric forms—each conferring unique functional consequences upon chromatin architecture. Researchers delineated that the dimeric form of MPO directly facilitates chromatin decondensation, a critical step in dismantling the tightly packed nucleosomal arrays that compose nuclear DNA. This decondensation enables the extrusion of chromatin fibers into the extracellular space, forming the characteristic NET structures that neutrophils deploy to trap and neutralize invading pathogens.

Strikingly, the mechanism through which dimeric MPO induces chromatin unfolding defies the canonical paradigms of chromatin remodeling. While typical chromatin remodelers rely on enzymatic activity fueled by ATP hydrolysis, MPO drives nucleosome disassembly without any energy expenditure, leveraging a unique molecular interaction with the nucleosome acidic patch. Structural analyses revealed that MPO’s binding mode mimics other nucleosome interactors but diverges by instigating a steric clash at nucleosomal DNA crossover sites. This clash destabilizes the DNA ends, promoting unwrapping and ultimately ejecting DNA from histone cores to disassemble the nucleosome.

Notably, the inherent dynamic nature of nucleosomes under physiological conditions provides a fertile ground for MPO’s disruptive influence. The transient exposure of DNA ends in untreated nucleosomes, which typically does not culminate in eviction, becomes exacerbated upon dimeric MPO binding. This effectively shifts the equilibrium from a stable chromatin state toward a decondensed configuration, underscoring how MPO acts as a molecular wedge facilitating nucleosome destabilization. These subtle yet decisive interactions highlight an unprecedented modality of chromatin transformation that operates independent of enzymatic chromatin remodeling machinery.

Conversely, monomeric MPO adopts a contrasting role by occupying the nucleosome’s acidic patch without inducing DNA displacement. Instead of promoting nucleosome eviction, monomeric MPO serves as a protective agent, shielding nucleosomes from the disruptive effects of their dimeric counterparts. This stable binding mode explains why monomeric MPO decorates extracellular NET structures, potentially amplifying their antimicrobial capacity through continued hypohalous acid production. The spatial detachment of MPO’s catalytic site from its DNA interaction surface enables this dual functionality, neatly segregating enzymatic and structural roles within the same protein complex.

The researchers propose a nuanced model of MPO action during NETosis whereby both oligomeric forms co-exist and compete for binding sites on chromatin. Initially, MPO binds chromatin weakly and non-specifically via DNA backbone interactions, before the acidic patch engagement locks either monomeric or dimeric MPO tightly onto nucleosomes. This competition determines the fate of chromatin domains, with some regions undergoing decondensation and disassembly driven by dimeric MPO, while others are preserved in compacted nucleosome–MPO complexes stabilized by the monomeric form. Such heterogeneity likely underpins the complex architecture of NETs and the multifaceted functional roles they play outside the cell.

Expanding beyond mechanistic details, this study challenges the classical definition of MPO deficiency, which has focused primarily on reduced catalytic activity. The newfound recognition of MPO’s chromatin-binding and nucleosome evicting capabilities invites a re-evaluation of this clinical phenotype. Functional impairments in chromatin interaction and destabilization could contribute to disease manifestations linked to defective NET formation, including infections, autoimmune disorders, and oncogenic processes. This research thus opens novel diagnostic and therapeutic avenues targeting the non-catalytic functions of MPO.

Importantly, MPO’s ability to irreversibly remodel chromatin into a biologically repurposed state diverges from any conventional chromatin remodeling complexes. Its action defines a new class of chromatin-transforming factors whose primary function is not gene regulation but rather structural and functional conversion of chromatin for immune defense purposes. This redefined chromatin state is characterized by a loss of replicative and transcriptional capacity, reflecting a fundamental alteration in chromatin identity, which empowers neutrophils to deploy NETs efficiently without maintaining genetic information integrity.

The evolutionary implications of such a repurposing mechanism are profound, suggesting that eukaryotic chromatin can serve as a versatile substrate adapted for diverse roles beyond its canonical functions. This paradigm may extend beyond neutrophils to other cell types and contexts, potentially involving similar or yet unidentified proteins that transform extracellular chromatin originating from necrotic or stressed cells into functionally adapted structures. The concept of chromatin versatility therefore acquires new significance, linking immunity, inflammation, and tissue homeostasis.

From a therapeutic perspective, deciphering the molecular basis of MPO-chromatin interaction offers strategic targets for modulating NET formation and activity. Inhibitors designed to prevent MPO binding to the nucleosome acidic patch could selectively disrupt chromatin decondensation during NETosis, thereby attenuating NET-driven pathological inflammation without compromising MPO’s enzymatic antimicrobial function. Such specificity holds promise for treating diseases exacerbated by excessive NET production, including sepsis, thrombosis, and autoimmune conditions.

The integration of high-resolution microscopy, cryogenic electron microscopy, and biochemical assays in this study provides an unprecedented structural framework to understand MPO’s dual modus operandi. The correlation between structural observations—ordered versus disordered nucleosomal DNA ends—and biochemical nucleosome stability highlights the dynamic interplay of molecular constraints imposed by MPO binding. This comprehensive approach underscores the power of multidisciplinary strategies to unravel complex biological phenomena at molecular resolution.

Overall, this illuminating research reveals myeloperoxidase as a versatile chromatin transformer at the crossroads of innate immunity and chromatin biology. By bridging structural biochemistry with immune cell function, it opens exciting new avenues for exploring how chromatin can be harnessed and adapted in diverse biological contexts. As we expand our knowledge of chromatin’s plasticity, MPO may serve as a prototype for an entirely new class of chromatin-altering proteins, redefining the cellular and extracellular roles of DNA and histone complexes in health and disease.

Subject of Research: The role of myeloperoxidase (MPO) in chromatin transformation during neutrophil extracellular trap (NET) formation and function.

Article Title: Myeloperoxidase transforms chromatin into neutrophil extracellular traps.

Article References:
Burn, G.L., Raisch, T., Tacke, S. et al. Myeloperoxidase transforms chromatin into neutrophil extracellular traps. Nature (2025). https://doi.org/10.1038/s41586-025-09523-9

Image Credits: AI Generated

Despite their crucial defensive role, NETs possess a double-edged nature, particularly within the renal milieu. Emerging evidence increasingly highlights how the dysregulated formation or impaired clearance of NETs can ignite deleterious inflammatory processes within the kidneys. The delicate architecture of the renal glomeruli and vasculature is especially susceptible to damage wrought by uncontrolled NET activity. The entrapment capabilities that serve to prevent microbial spread paradoxically induce vascular occlusion, endothelial injury, and precipitate a cascade of immune reactions detrimental to kidney function.

A comprehensive review recently published in Nature Reviews Nephrology by Professor Akihiro Ishizu and colleagues from Hokkaido University delves deeply into the multifaceted involvement of neutrophils and their extracellular traps in kidney pathology. By synthesizing a broad spectrum of studies, the review delineates how aberrant NET dynamics contribute to a variety of kidney diseases. These conditions, including ANCA-associated vasculitis, systemic lupus erythematosus-induced nephritis, thrombotic microangiopathy, diabetic nephropathy, and crystal-induced kidney injuries, share a common thread of NET-driven inflammation and tissue destabilization.

Neutrophil activation, a prerequisite for NET release, involves complex signaling pathways. Among these, the complement component C5a emerges as a pivotal chemoattractant and activator, instigating neutrophil recruitment and priming within inflamed renal tissues. Pharmacologic antagonists targeting the C5a receptor, such as avacopan, have demonstrated promising clinical efficacy by dampening pathogenic neutrophil activation. This therapeutic strategy exemplifies a paradigm shift, moving away from broad immunosuppression toward precision modulation of neutrophil-induced damage.

The enzymatic orchestration of NETosis—the process culminating in NET generation—relies heavily on enzymes such as neutrophil elastase and peptidylarginine deiminase 4 (PAD4). These enzymes facilitate chromatin decondensation and nuclear membrane disruption, essential steps for the extrusion of DNA webs. Efforts to inhibit these enzymes pharmacologically have gained momentum, aiming to prevent NET formation and thus halt the downstream inflammatory amplification that compromises renal structures.

Clearance mechanisms for NETs are equally vital in maintaining renal homeostasis. Enzymes including DNase I and DNase1L3 biologically dismantle extracellular DNA scaffolds, facilitating the resolution of inflammatory sites. However, in chronic kidney diseases, NETs often exhibit biochemical modifications that confer resistance to enzymatic degradation, perpetuating immune activation and fibrosis. Understanding the molecular attributes conferring this resilience to NETs represents a forefront area of nephrology research.

The pathogenic role of NETs extends beyond mere physical obstruction; they serve as potent stimulators of immune cell recruitment and activation. By exposing nuclear and granular proteins abnormally to the immune system, NETs can instigate autoimmunity, exacerbating autoimmune nephritides such as lupus nephritis and ANCA-associated vasculitis. The resultant cycles of injury and repair overwhelm intrinsic renal regenerative capacities, progressing toward chronic kidney disease and potential failure.

Therapeutic targeting of NET-related pathways offers a tantalizing prospect for revolutionizing kidney disease management. Traditional immunosuppressive regimens, while effective in curbing generalized inflammation, leave patients vulnerable to infections and malignancies. In contrast, interventions honed to neutrophil-specific signaling and effector functions promise to attenuate destructive inflammation with greater safety profiles. Such precision medicine approaches may curtail disease progression while preserving host defense integrity.

The review also underscores the necessity for translational research bridging benchside discoveries to bedside applications. Several clinical trials evaluating NET-inhibitory agents and C5a receptor antagonists are underway or forthcoming, poised to refine treatment paradigms for inflammatory kidney diseases. These advances herald a future where modulation of innate immune effector mechanisms directly ameliorates organ-specific pathology.

Looking ahead, integrative analyses combining proteomics, genomics, and advanced imaging of NET dynamics will illuminate individual variability in kidney disease susceptibility and progression. Personalized therapies, designed to intercept neutrophil-mediated injury based on patient-specific biomarkers, might emerge as the new standard of care. Such approaches could mitigate renal inflammation with unprecedented specificity, reducing chronic kidney disease burden globally.

In summation, the evolving understanding of neutrophils and their extracellular traps in renal pathology reshapes longstanding conceptions of kidney disease etiology. Far from passive bystanders, these immune effector mechanisms actively orchestrate tissue damage and healing imbalances. Harnessing this knowledge ushers in innovative therapeutic avenues emphasizing immune precision, potentially transforming prognosis for millions impacted by kidney diseases worldwide.

Subject of Research: Cells
Article Title: Neutrophils and NETs in kidney disease
News Publication Date: 18-Mar-2025
Web References: 10.1038/s41581-025-00944-3
Image Credits: Akihiro Ishizu, Hokkaido University
Keywords: Immunology, Cellular physiology